DDI Drug Name |
DDI Drug ID |
Severity |
Mechanism |
Comorbidity |
REF |
Methylergonovine |
DMBEX4O
|
Moderate |
Decreased metabolism of Ranolazine caused by Methylergonovine mediated inhibition of CYP450 enzyme. |
Abortion [JA00]
|
[16] |
Sarecycline |
DMLZNIQ
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Sarecycline . |
Acne vulgaris [ED80]
|
[15] |
Ivosidenib |
DM8S6T7
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Ivosidenib. |
Acute myeloid leukaemia [2A60]
|
[17] |
Midostaurin |
DMI6E0R
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Midostaurin. |
Acute myeloid leukaemia [2A60]
|
[18] |
Idarubicin |
DMM0XGL
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Idarubicin. |
Acute myeloid leukaemia [2A60]
|
[19] |
Daunorubicin |
DMQUSBT
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Daunorubicin. |
Acute myeloid leukaemia [2A60]
|
[19] |
Arn-509 |
DMT81LZ
|
Major |
Increased metabolism of Ranolazine caused by Arn-509 mediated induction of CYP450 enzyme. |
Acute myeloid leukaemia [2A60]
|
[15] |
Gilteritinib |
DMTI0ZO
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Gilteritinib. |
Acute myeloid leukaemia [2A60]
|
[20] |
Oliceridine |
DM6MDCF
|
Major |
Decreased metabolism of Ranolazine caused by Oliceridine mediated inhibition of CYP450 enzyme. |
Acute pain [MG31]
|
[21] |
Mitotane |
DMU1GX0
|
Major |
Increased metabolism of Ranolazine caused by Mitotane mediated induction of CYP450 enzyme. |
Adrenal cancer [2D11]
|
[15] |
Terfenadine |
DM4KLPT
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Terfenadine. |
Allergic/hypersensitivity disorder [4A80-4A8Z]
|
[18] |
Tripelennamine |
DMZBU15
|
Minor |
Decreased metabolism of Ranolazine caused by Tripelennamine mediated inhibition of CYP450 enzyme. |
Allergic/hypersensitivity disorder [4A80-4A8Z]
|
[15] |
Tacrine |
DM51FY6
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Ranolazine and Tacrine. |
Alzheimer disease [8A20]
|
[14] |
Galantamine |
DMEO794
|
Moderate |
Decreased metabolism of Ranolazine caused by Galantamine mediated inhibition of CYP450 enzyme. |
Alzheimer disease [8A20]
|
[15] |
Rivastigmine |
DMG629M
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Ranolazine and Rivastigmine. |
Alzheimer disease [8A20]
|
[14] |
Donepezil |
DMIYG7Z
|
Minor |
Decreased metabolism of Ranolazine caused by Donepezil mediated inhibition of CYP450 enzyme. |
Alzheimer disease [8A20]
|
[22] |
Metronidazole |
DMTIVEN
|
Minor |
Increased risk of prolong QT interval by the combination of Ranolazine and Metronidazole. |
Amoebiasis [1A36]
|
[23] |
Bedaquiline |
DM3906J
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Bedaquiline. |
Antimicrobial drug resistance [MG50-MG52]
|
[24] |
Methylphenobarbital |
DMDSWAG
|
Major |
Increased metabolism of Ranolazine caused by Methylphenobarbital mediated induction of CYP450 enzyme. |
Anxiety disorder [6B00-6B0Z]
|
[25] |
Hydroxyzine |
DMF8Y74
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Hydroxyzine. |
Anxiety disorder [6B00-6B0Z]
|
[18] |
Clobazam - Lundbeck |
DMW1OQ0
|
Minor |
Decreased metabolism of Ranolazine caused by Clobazam - Lundbeck mediated inhibition of CYP450 enzyme. |
Anxiety disorder [6B00-6B0Z]
|
[15] |
Promazine |
DMZAL7W
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Promazine. |
Appearance/behaviour symptom [MB23]
|
[18] |
Voriconazole |
DMAOL2S
|
Major |
Decreased metabolism of Ranolazine caused by Voriconazole mediated inhibition of CYP450 enzyme. |
Aspergillosis [1F20]
|
[23] |
Posaconazole |
DMUL5EW
|
Major |
Decreased metabolism of Ranolazine caused by Posaconazole mediated inhibition of CYP450 enzyme. |
Aspergillosis [1F20]
|
[23] |
Levalbuterol |
DM5YBO1
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Ranolazine and Levalbuterol. |
Asthma [CA23]
|
[26] |
Terbutaline |
DMD4381
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Ranolazine and Terbutaline. |
Asthma [CA23]
|
[27] |
Pirbuterol |
DMI5678
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Ranolazine and Pirbuterol. |
Asthma [CA23]
|
[27] |
Budesonide |
DMJIBAW
|
Moderate |
Decreased metabolism of Ranolazine caused by Budesonide mediated inhibition of CYP450 enzyme. |
Asthma [CA23]
|
[28] |
Salbutamol |
DMN9CWF
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Salbutamol. |
Asthma [CA23]
|
[26] |
Formoterol |
DMSOURV
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Ranolazine and Formoterol. |
Asthma [CA23]
|
[27] |
Pimecrolimus |
DMZLGRB
|
Minor |
Decreased metabolism of Ranolazine caused by Pimecrolimus mediated inhibition of CYP450 enzyme. |
Atopic eczema [EA80]
|
[29] |
Atomoxetine |
DM5L6HI
|
Moderate |
Decreased metabolism of Ranolazine caused by Atomoxetine mediated inhibition of CYP450 enzyme. |
Attention deficit hyperactivity disorder [6A05]
|
[30] |
Lisdexamfetamine |
DM6W8V5
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Lisdexamfetamine. |
Attention deficit hyperactivity disorder [6A05]
|
[20] |
Desipramine |
DMT2FDC
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Desipramine. |
Attention deficit hyperactivity disorder [6A05]
|
[18] |
Ofloxacin |
DM0VQN3
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Ofloxacin. |
Bacterial infection [1A00-1C4Z]
|
[18] |
Ciprofloxacin XR |
DM2NLS9
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Ciprofloxacin XR. |
Bacterial infection [1A00-1C4Z]
|
[18] |
Dalfopristin |
DM4LTKV
|
Major |
Decreased metabolism of Ranolazine caused by Dalfopristin mediated inhibition of CYP450 enzyme. |
Bacterial infection [1A00-1C4Z]
|
[18] |
Clarithromycin |
DM4M1SG
|
Major |
Decreased metabolism of Ranolazine caused by Clarithromycin mediated inhibition of CYP450 enzyme. |
Bacterial infection [1A00-1C4Z]
|
[23] |
Sulfamethoxazole |
DMB08GE
|
Minor |
Increased risk of prolong QT interval by the combination of Ranolazine and Sulfamethoxazole. |
Bacterial infection [1A00-1C4Z]
|
[14] |
Sparfloxacin |
DMB4HCT
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Sparfloxacin. |
Bacterial infection [1A00-1C4Z]
|
[31] |
Gemifloxacin |
DMHT34O
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Gemifloxacin. |
Bacterial infection [1A00-1C4Z]
|
[18] |
Norfloxacin |
DMIZ6W2
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Norfloxacin. |
Bacterial infection [1A00-1C4Z]
|
[18] |
Levofloxacin |
DMS60RB
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Levofloxacin. |
Bacterial infection [1A00-1C4Z]
|
[18] |
Lomefloxacin |
DMVRH9C
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Lomefloxacin. |
Bacterial infection [1A00-1C4Z]
|
[18] |
Telithromycin |
DMZ4P3A
|
Major |
Decreased metabolism of Ranolazine caused by Telithromycin mediated inhibition of CYP450 enzyme. |
Bacterial infection [1A00-1C4Z]
|
[23] |
Retigabine |
DMGNYIH
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Retigabine. |
Behcet disease [4A62]
|
[18] |
Cariprazine |
DMJYDVK
|
Moderate |
Decreased metabolism of Ranolazine caused by Cariprazine mediated inhibition of CYP450 enzyme. |
Bipolar disorder [6A60]
|
[20] |
Erdafitinib |
DMI782S
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Erdafitinib. |
Bladder cancer [2C94]
|
[32] |
Loperamide |
DMOJZQ9
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Loperamide. |
Bowel habit change [ME05]
|
[33] |
Eribulin |
DM1DX4Q
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Eribulin. |
Breast cancer [2C60-2C6Y]
|
[14] |
Talazoparib |
DM1KS78
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Talazoparib. |
Breast cancer [2C60-2C6Y]
|
[20] |
Lapatinib |
DM3BH1Y
|
Major |
Decreased metabolism of Ranolazine caused by Lapatinib mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[15] |
LY2835219 |
DM93VBZ
|
Moderate |
Decreased metabolism of Ranolazine caused by LY2835219 mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[34] |
Tucatinib |
DMBESUA
|
Major |
Decreased metabolism of Ranolazine caused by Tucatinib mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[23] |
Palbociclib |
DMD7L94
|
Moderate |
Decreased metabolism of Ranolazine caused by Palbociclib mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[20] |
Alpelisib |
DMEXMYK
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Alpelisib. |
Breast cancer [2C60-2C6Y]
|
[15] |
Tamoxifen |
DMLB0EZ
|
Major |
Decreased metabolism of Ranolazine caused by Tamoxifen mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[35] |
Cabazitaxel |
DMPAZHC
|
Moderate |
Decreased metabolism of Ranolazine caused by Cabazitaxel mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[36] |
Toremifene |
DMQYUWG
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Toremifene. |
Breast cancer [2C60-2C6Y]
|
[14] |
Bosutinib |
DMTI8YE
|
Moderate |
Decreased metabolism of Ranolazine caused by Bosutinib mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[20] |
Grepafloxacin |
DMGLX0T
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Grepafloxacin. |
Bronchitis [CA20]
|
[31] |
Sotalol |
DML60TN
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Sotalol. |
Cardiac arrhythmia [BC9Z]
|
[14] |
Atorvastatin |
DMF28YC
|
Major |
Decreased metabolism of Ranolazine caused by Atorvastatin mediated inhibition of CYP450 enzyme. |
Cardiovascular disease [BA00-BE2Z]
|
[20] |
Macitentan |
DMP79A1
|
Moderate |
Decreased metabolism of Ranolazine caused by Macitentan mediated inhibition of CYP450 enzyme. |
Cardiovascular disease [BA00-BE2Z]
|
[37] |
Secobarbital |
DM14RF5
|
Major |
Increased metabolism of Ranolazine caused by Secobarbital mediated induction of CYP450 enzyme. |
Chronic insomnia [7A00]
|
[15] |
Olodaterol |
DM62B78
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Ranolazine and Olodaterol. |
Chronic obstructive pulmonary disease [CA22]
|
[27] |
Vilanterol |
DMF5EK1
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Ranolazine and Vilanterol. |
Chronic obstructive pulmonary disease [CA22]
|
[26] |
Salmeterol |
DMIEU69
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Ranolazine and Salmeterol. |
Chronic obstructive pulmonary disease [CA22]
|
[27] |
Indacaterol |
DMQJHR7
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Ranolazine and Indacaterol. |
Chronic obstructive pulmonary disease [CA22]
|
[27] |
Arformoterol |
DMYM974
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Ranolazine and Arformoterol. |
Chronic obstructive pulmonary disease [CA22]
|
[27] |
Phenylbutazone |
DMAYL0T
|
Major |
Increased metabolism of Ranolazine caused by Phenylbutazone mediated induction of CYP450 enzyme. |
Chronic pain [MG30]
|
[15] |
Fidaxomicin |
DMFP6MV
|
Minor |
Decreased clearance of Ranolazine due to the transporter inhibition by Fidaxomicin. |
Clostridium difficile enterocolitis [1A04]
|
[23] |
Irinotecan |
DMP6SC2
|
Moderate |
Decreased metabolism of Ranolazine caused by Irinotecan mediated inhibition of CYP450 enzyme. |
Colorectal cancer [2B91]
|
[14] |
Oxaliplatin |
DMQNWRD
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Oxaliplatin. |
Colorectal cancer [2B91]
|
[18] |
Intedanib |
DMSTA36
|
Moderate |
Decreased metabolism of Ranolazine caused by Intedanib mediated inhibition of CYP450 enzyme. |
Colorectal cancer [2B91]
|
[38] |
Isoproterenol |
DMK7MEY
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Isoproterenol. |
Conduction disorder [BC63]
|
[26] |
Ulipristal |
DMBNI20
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Ulipristal. |
Contraceptive management [QA21]
|
[15] |
Halothane |
DM80OZ5
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Halothane. |
Corneal disease [9A76-9A78]
|
[18] |
Propofol |
DMB4OLE
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Propofol. |
Corneal disease [9A76-9A78]
|
[39] |
Ropivacaine |
DMSPJG2
|
Minor |
Decreased metabolism of Ranolazine caused by Ropivacaine mediated inhibition of CYP450 enzyme. |
Corneal disease [9A76-9A78]
|
[40] |
Alfentanil |
DMVO0UB
|
Moderate |
Decreased metabolism of Ranolazine caused by Alfentanil mediated inhibition of CYP450 enzyme. |
Corneal disease [9A76-9A78]
|
[41] |
Probucol |
DMVZQ2M
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Probucol. |
Coronary atherosclerosis [BA80]
|
[18] |
Methadone |
DMTW6IU
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Methadone. |
Cough [MD12]
|
[14] |
Dextromethorphan |
DMUDJZM
|
Moderate |
Decreased metabolism of Ranolazine caused by Dextromethorphan mediated inhibition of CYP450 enzyme. |
Cough [MD12]
|
[23] |
Clofazimine |
DMEBOFW
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Clofazimine. |
Crohn disease [DD70]
|
[42] |
Pasireotide |
DMHM7JS
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Pasireotide. |
Cushing syndrome [5A70]
|
[14] |
Aminoglutethimide |
DMWFHMZ
|
Major |
Increased metabolism of Ranolazine caused by Aminoglutethimide mediated induction of CYP450 enzyme. |
Cushing syndrome [5A70]
|
[15] |
Lumacaftor |
DMCLWDJ
|
Major |
Increased metabolism of Ranolazine caused by Lumacaftor mediated induction of CYP450 enzyme. |
Cystic fibrosis [CA25]
|
[25] |
Ivacaftor |
DMZC1HS
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Ivacaftor. |
Cystic fibrosis [CA25]
|
[15] |
MK-8228 |
DMOB58Q
|
Major |
Decreased metabolism of Ranolazine caused by MK-8228 mediated inhibition of CYP450 enzyme. |
Cytomegaloviral disease [1D82]
|
[15] |
Rivaroxaban |
DMQMBZ1
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Rivaroxaban. |
Deep vein thrombosis [BD71]
|
[43] |
Aprepitant |
DM053KT
|
Major |
Decreased metabolism of Ranolazine caused by Aprepitant mediated inhibition of CYP450 enzyme. |
Depression [6A70-6A7Z]
|
[15] |
Sertraline |
DM0FB1J
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Sertraline. |
Depression [6A70-6A7Z]
|
[18] |
Trimipramine |
DM1SC8M
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Trimipramine. |
Depression [6A70-6A7Z]
|
[18] |
Imipramine |
DM2NUH3
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Imipramine. |
Depression [6A70-6A7Z]
|
[18] |
Fluoxetine |
DM3PD2C
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Fluoxetine. |
Depression [6A70-6A7Z]
|
[18] |
Nortriptyline |
DM4KDYJ
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Nortriptyline. |
Depression [6A70-6A7Z]
|
[18] |
Nefazodone |
DM4ZS8M
|
Major |
Decreased metabolism of Ranolazine caused by Nefazodone mediated inhibition of CYP450 enzyme. |
Depression [6A70-6A7Z]
|
[23] |
Paroxetine |
DM5PVQE
|
Moderate |
Decreased metabolism of Ranolazine caused by Paroxetine mediated inhibition of CYP450 enzyme. |
Depression [6A70-6A7Z]
|
[15] |
Duloxetine |
DM9BI7M
|
Moderate |
Decreased metabolism of Ranolazine caused by Duloxetine mediated inhibition of CYP450 enzyme. |
Depression [6A70-6A7Z]
|
[44] |
Escitalopram |
DMFK9HG
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Escitalopram. |
Depression [6A70-6A7Z]
|
[14] |
OPC-34712 |
DMHG57U
|
Major |
Decreased metabolism of Ranolazine caused by OPC-34712 mediated inhibition of CYP450 enzyme. |
Depression [6A70-6A7Z]
|
[45] |
Clomipramine |
DMINRKW
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Clomipramine. |
Depression [6A70-6A7Z]
|
[18] |
Trazodone |
DMK1GBJ
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Trazodone. |
Depression [6A70-6A7Z]
|
[46] |
Amitriptyline |
DMK7F9S
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Amitriptyline. |
Depression [6A70-6A7Z]
|
[18] |
Amoxapine |
DMKITQE
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Amoxapine. |
Depression [6A70-6A7Z]
|
[18] |
Mirtazapine |
DML53ZJ
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Mirtazapine. |
Depression [6A70-6A7Z]
|
[47] |
Protriptyline |
DMNHTZI
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Protriptyline. |
Depression [6A70-6A7Z]
|
[18] |
Doxepin |
DMPI98T
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Doxepin. |
Depression [6A70-6A7Z]
|
[18] |
Maprotiline |
DMPWB7T
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Maprotiline. |
Depression [6A70-6A7Z]
|
[18] |
Venlafaxine |
DMR6QH0
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Venlafaxine. |
Depression [6A70-6A7Z]
|
[18] |
Griseofulvin |
DMK54YG
|
Major |
Increased metabolism of Ranolazine caused by Griseofulvin mediated induction of CYP450 enzyme. |
Dermatophytosis [1F28]
|
[15] |
Polatuzumab vedotin |
DMF6Y0L
|
Moderate |
Decreased metabolism of Ranolazine caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. |
Diffuse large B-cell lymphoma [2A81]
|
[48] |
Tetrabenazine |
DMYWQ0O
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Tetrabenazine. |
Dissociative neurological symptom disorder [6B60]
|
[18] |
Fenfluramine |
DM0762O
|
Moderate |
Decreased metabolism of Ranolazine caused by Fenfluramine mediated inhibition of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[15] |
Primidone |
DM0WX6I
|
Major |
Increased metabolism of Ranolazine caused by Primidone mediated induction of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[15] |
Felbamate |
DM1V5ZS
|
Major |
Increased metabolism of Ranolazine caused by Felbamate mediated induction of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[15] |
Oxcarbazepine |
DM5PU6O
|
Major |
Increased metabolism of Ranolazine caused by Oxcarbazepine mediated induction of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[15] |
Cenobamate |
DM8KLU9
|
Major |
Increased metabolism of Ranolazine caused by Cenobamate mediated induction of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[15] |
Stiripentol |
DMMSDOY
|
Moderate |
Decreased metabolism of Ranolazine caused by Stiripentol mediated inhibition of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[20] |
Fosphenytoin |
DMOX3LB
|
Major |
Increased metabolism of Ranolazine caused by Fosphenytoin mediated induction of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[15] |
Phenobarbital |
DMXZOCG
|
Major |
Increased metabolism of Ranolazine caused by Phenobarbital mediated induction of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[15] |
Diphenhydramine |
DMKQTBA
|
Moderate |
Decreased metabolism of Ranolazine caused by Diphenhydramine mediated inhibition of CYP450 enzyme. |
Episodic vestibular syndrome [AB31]
|
[15] |
Timolol |
DM3NXRU
|
Moderate |
Decreased metabolism of Ranolazine caused by Timolol mediated inhibition of CYP450 enzyme. |
Essential hypertension [BA00]
|
[15] |
Nicardipine |
DMCDYW7
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Nicardipine. |
Essential hypertension [BA00]
|
[15] |
Bay 80-6946 |
DMLOS5R
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Bay 80-6946. |
Follicular lymphoma [2A80]
|
[49] |
Tazemetostat |
DMWP1BH
|
Major |
Increased metabolism of Ranolazine caused by Tazemetostat mediated induction of CYP450 enzyme. |
Follicular lymphoma [2A80]
|
[15] |
Solifenacin |
DMG592Q
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Solifenacin. |
Functional bladder disorder [GC50]
|
[18] |
Mirabegron |
DMS1GYT
|
Minor |
Decreased metabolism of Ranolazine caused by Mirabegron mediated inhibition of CYP450 enzyme. |
Functional bladder disorder [GC50]
|
[15] |
Tolterodine |
DMSHPW8
|
Minor |
Decreased metabolism of Ranolazine caused by Tolterodine mediated inhibition of CYP450 enzyme. |
Functional bladder disorder [GC50]
|
[50] |
Darifenacin |
DMWXLYZ
|
Moderate |
Decreased metabolism of Ranolazine caused by Darifenacin mediated inhibition of CYP450 enzyme. |
Functional bladder disorder [GC50]
|
[51] |
Itraconazole |
DMCR1MV
|
Major |
Decreased metabolism of Ranolazine caused by Itraconazole mediated inhibition of CYP450 enzyme. |
Fungal infection [1F29-1F2F]
|
[23] |
Pentamidine |
DMHZJCG
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Pentamidine. |
Fungal infection [1F29-1F2F]
|
[18] |
Terbinafine |
DMI6HUW
|
Minor |
Decreased metabolism of Ranolazine caused by Terbinafine mediated inhibition of CYP450 enzyme. |
Fungal infection [1F29-1F2F]
|
[15] |
Clotrimazole |
DMMFCIH
|
Major |
Decreased metabolism of Ranolazine caused by Clotrimazole mediated inhibition of CYP450 enzyme. |
Fungal infection [1F29-1F2F]
|
[15] |
Miconazole |
DMPMYE8
|
Moderate |
Decreased metabolism of Ranolazine caused by Miconazole mediated inhibition of CYP450 enzyme. |
Fungal infection [1F29-1F2F]
|
[52] |
Ketoconazole |
DMPZI3Q
|
Major |
Decreased metabolism of Ranolazine caused by Ketoconazole mediated inhibition of CYP450 enzyme. |
Fungal infection [1F29-1F2F]
|
[23] |
Cimetidine |
DMH61ZB
|
Minor |
Decreased metabolism of Ranolazine caused by Cimetidine mediated inhibition of CYP450 enzyme. |
Gastro-oesophageal reflux disease [DA22]
|
[15] |
Cisapride |
DMY7PED
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Cisapride. |
Gastro-oesophageal reflux disease [DA22]
|
[14] |
Ripretinib |
DM958QB
|
Moderate |
Decreased metabolism of Ranolazine caused by Ripretinib mediated inhibition of CYP450 enzyme. |
Gastrointestinal stromal tumour [2B5B]
|
[23] |
Sunitinib |
DMCBJSR
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Sunitinib. |
Gastrointestinal stromal tumour [2B5B]
|
[18] |
Avapritinib |
DMK2GZX
|
Moderate |
Decreased metabolism of Ranolazine caused by Avapritinib mediated inhibition of CYP450 enzyme. |
Gastrointestinal stromal tumour [2B5B]
|
[20] |
Sulfinpyrazone |
DMEV954
|
Major |
Increased metabolism of Ranolazine caused by Sulfinpyrazone mediated induction of CYP450 enzyme. |
Gout [FA25]
|
[15] |
Ergotamine |
DMKR3C5
|
Moderate |
Decreased metabolism of Ranolazine caused by Ergotamine mediated inhibition of CYP450 enzyme. |
Headache [8A80-8A84]
|
[53] |
Spironolactone |
DM2AQ5N
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Spironolactone. |
Heart failure [BD10-BD1Z]
|
[15] |
Carvedilol |
DMHTEAO
|
Moderate |
Decreased metabolism of Ranolazine caused by Carvedilol mediated inhibition of CYP450 enzyme. |
Heart failure [BD10-BD1Z]
|
[15] |
Boceprevir |
DMBSHMF
|
Major |
Decreased metabolism of Ranolazine caused by Boceprevir mediated inhibition of CYP450 enzyme. |
Hepatitis virus infection [1E50-1E51]
|
[23] |
Telaprevir |
DMMRV29
|
Major |
Decreased metabolism of Ranolazine caused by Telaprevir mediated inhibition of CYP450 enzyme. |
Hepatitis virus infection [1E50-1E51]
|
[23] |
GS-5885 |
DMSL3DX
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by GS-5885. |
Hepatitis virus infection [1E50-1E51]
|
[15] |
Rifampin |
DMA8J1G
|
Major |
Increased metabolism of Ranolazine caused by Rifampin mediated induction of CYP450 enzyme. |
HIV-infected patients with tuberculosis [1B10-1B14]
|
[25] |
Rifapentine |
DMCHV4I
|
Major |
Increased metabolism of Ranolazine caused by Rifapentine mediated induction of CYP450 enzyme. |
HIV-infected patients with tuberculosis [1B10-1B14]
|
[15] |
Brentuximab vedotin |
DMWLC57
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Brentuximab vedotin. |
Hodgkin lymphoma [2B30]
|
[54] |
MK-1439 |
DM215WE
|
Minor |
Decreased metabolism of Ranolazine caused by MK-1439 mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[55] |
Delavirdine |
DM3NF5G
|
Major |
Decreased metabolism of Ranolazine caused by Delavirdine mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[23] |
Fosamprenavir |
DM4W9B3
|
Major |
Decreased metabolism of Ranolazine caused by Fosamprenavir mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[23] |
Fostemsavir |
DM50ILT
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Fostemsavir. |
Human immunodeficiency virus disease [1C60-1C62]
|
[18] |
Cobicistat |
DM6L4H2
|
Major |
Decreased metabolism of Ranolazine caused by Cobicistat mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[23] |
Efavirenz |
DMC0GSJ
|
Major |
Increased metabolism of Ranolazine caused by Efavirenz mediated induction of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[15] |
Saquinavir |
DMG814N
|
Major |
Decreased metabolism of Ranolazine caused by Saquinavir mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[23] |
Etravirine |
DMGV8QU
|
Major |
Increased metabolism of Ranolazine caused by Etravirine mediated induction of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[15] |
Rilpivirine |
DMJ0QOW
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Rilpivirine. |
Human immunodeficiency virus disease [1C60-1C62]
|
[18] |
Amprenavir |
DMLMXE0
|
Major |
Decreased metabolism of Ranolazine caused by Amprenavir mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[23] |
Darunavir |
DMN3GCH
|
Major |
Decreased metabolism of Ranolazine caused by Darunavir mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[23] |
Atazanavir |
DMSYRBX
|
Major |
Decreased metabolism of Ranolazine caused by Atazanavir mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[23] |
Maraviroc |
DMTL94F
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Maraviroc. |
Human immunodeficiency virus disease [1C60-1C62]
|
[56] |
Simvastatin |
DM30SGU
|
Major |
Decreased metabolism of Ranolazine caused by Simvastatin mediated inhibition of CYP450 enzyme. |
Hyper-lipoproteinaemia [5C80]
|
[20] |
BMS-201038 |
DMQTAGO
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by BMS-201038. |
Hyper-lipoproteinaemia [5C80]
|
[57] |
Cerivastatin |
DMXCM7H
|
Moderate |
Decreased metabolism of Ranolazine caused by Cerivastatin mediated inhibition of CYP450 enzyme. |
Hyper-lipoproteinaemia [5C80]
|
[58] |
Cinacalcet |
DMCX0K3
|
Minor |
Decreased metabolism of Ranolazine caused by Cinacalcet mediated inhibition of CYP450 enzyme. |
Hyper-parathyroidism [5A51]
|
[15] |
Aliskiren |
DM1BV7W
|
Moderate |
Decreased metabolism of Ranolazine caused by Aliskiren mediated inhibition of CYP450 enzyme. |
Hypertension [BA00-BA04]
|
[14] |
Nebivolol |
DM7F1PA
|
Moderate |
Decreased metabolism of Ranolazine caused by Nebivolol mediated inhibition of CYP450 enzyme. |
Hypertension [BA00-BA04]
|
[15] |
Verapamil |
DMA7PEW
|
Major |
Decreased metabolism of Ranolazine caused by Verapamil mediated inhibition of CYP450 enzyme. |
Hypertension [BA00-BA04]
|
[15] |
Diltiazem |
DMAI7ZV
|
Major |
Decreased metabolism of Ranolazine caused by Diltiazem mediated inhibition of CYP450 enzyme. |
Hypertension [BA00-BA04]
|
[15] |
Pindolol |
DMD2NV7
|
Moderate |
Decreased metabolism of Ranolazine caused by Pindolol mediated inhibition of CYP450 enzyme. |
Hypertension [BA00-BA04]
|
[15] |
Metoprolol |
DMOJ0V6
|
Moderate |
Decreased metabolism of Ranolazine caused by Metoprolol mediated inhibition of CYP450 enzyme. |
Hypertension [BA00-BA04]
|
[15] |
Felodipine |
DMOSW35
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Felodipine. |
Hypertension [BA00-BA04]
|
[15] |
Conivaptan |
DM1V329
|
Major |
Decreased metabolism of Ranolazine caused by Conivaptan mediated inhibition of CYP450 enzyme. |
Hypo-osmolality/hyponatraemia [5C72]
|
[15] |
Tolvaptan |
DMIWFRL
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Tolvaptan. |
Hypo-osmolality/hyponatraemia [5C72]
|
[59] |
Pirfenidone |
DM6VZFQ
|
Moderate |
Decreased metabolism of Ranolazine caused by Pirfenidone mediated inhibition of CYP450 enzyme. |
Idiopathic interstitial pneumonitis [CB03]
|
[20] |
Givosiran |
DM5PFIJ
|
Minor |
Decreased metabolism of Ranolazine caused by Givosiran mediated inhibition of CYP450 enzyme. |
Inborn porphyrin/heme metabolism error [5C58]
|
[15] |
Berotralstat |
DMWA2DZ
|
Major |
Decreased clearance of Ranolazine due to the transporter inhibition by Berotralstat. |
Innate/adaptive immunodeficiency [4A00]
|
[60] |
Suvorexant |
DM0E6S3
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Suvorexant. |
Insomnia [7A00-7A0Z]
|
[15] |
Amobarbital |
DM0GQ8N
|
Major |
Increased metabolism of Ranolazine caused by Amobarbital mediated induction of CYP450 enzyme. |
Insomnia [7A00-7A0Z]
|
[15] |
Pentobarbital |
DMFNH7L
|
Major |
Increased metabolism of Ranolazine caused by Pentobarbital mediated induction of CYP450 enzyme. |
Insomnia [7A00-7A0Z]
|
[15] |
ITI-007 |
DMUQ1DO
|
Moderate |
Decreased metabolism of Ranolazine caused by ITI-007 mediated inhibition of CYP450 enzyme. |
Insomnia [7A00-7A0Z]
|
[61] |
Polyethylene glycol |
DM4I1JP
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Ranolazine and Polyethylene glycol. |
Irritable bowel syndrome [DD91]
|
[20] |
Phenolphthalein |
DM5SICT
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Ranolazine and Phenolphthalein. |
Irritable bowel syndrome [DD91]
|
[14] |
Naloxegol |
DML0B41
|
Minor |
Decreased metabolism of Ranolazine caused by Naloxegol mediated inhibition of CYP450 enzyme. |
Large intestine motility disorder [DB32]
|
[62] |
Pemigatinib |
DM819JF
|
Moderate |
Decreased metabolism of Ranolazine caused by Pemigatinib mediated inhibition of CYP450 enzyme. |
Liver cancer [2C12]
|
[20] |
Glycerol phenylbutyrate |
DMDGRQO
|
Minor |
Decreased metabolism of Ranolazine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. |
Liver disease [DB90-DB9Z]
|
[15] |
Crizotinib |
DM4F29C
|
Major |
Decreased metabolism of Ranolazine caused by Crizotinib mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[15] |
Brigatinib |
DM7W94S
|
Moderate |
Decreased metabolism of Ranolazine caused by Brigatinib mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[23] |
Lurbinectedin |
DMEFRTZ
|
Moderate |
Decreased metabolism of Ranolazine caused by Lurbinectedin mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[63] |
PF-06463922 |
DMKM7EW
|
Major |
Increased metabolism of Ranolazine caused by PF-06463922 mediated induction of CYP450 enzyme. |
Lung cancer [2C25]
|
[15] |
Dacomitinib |
DMOH8VY
|
Minor |
Decreased metabolism of Ranolazine caused by Dacomitinib mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[15] |
Osimertinib |
DMRJLAT
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Osimertinib. |
Lung cancer [2C25]
|
[64] |
Pralsetinib |
DMWU0I2
|
Moderate |
Decreased metabolism of Ranolazine caused by Pralsetinib mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[65] |
Capmatinib |
DMYCXKL
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Capmatinib. |
Lung cancer [2C25]
|
[15] |
Selpercatinib |
DMZR15V
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Selpercatinib. |
Lung cancer [2C25]
|
[20] |
Lumefantrine |
DM29GAD
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Lumefantrine. |
Malaria [1F40-1F45]
|
[23] |
Halofantrine |
DMOMK1V
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Halofantrine. |
Malaria [1F40-1F45]
|
[66] |
Chloroquine |
DMSI5CB
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Chloroquine. |
Malaria [1F40-1F45]
|
[67] |
Hydroxychloroquine |
DMSIVND
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Hydroxychloroquine. |
Malaria [1F40-1F45]
|
[67] |
Quinine |
DMSWYF5
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Quinine. |
Malaria [1F40-1F45]
|
[18] |
Primaquine |
DMWQ16I
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Primaquine. |
Malaria [1F40-1F45]
|
[18] |
Mefloquine |
DMWT905
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Mefloquine. |
Malaria [1F40-1F45]
|
[18] |
Inotuzumab ozogamicin |
DMAC130
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Inotuzumab ozogamicin. |
Malignant haematopoietic neoplasm [2B33]
|
[18] |
Idelalisib |
DM602WT
|
Major |
Decreased metabolism of Ranolazine caused by Idelalisib mediated inhibition of CYP450 enzyme. |
Mature B-cell leukaemia [2A82]
|
[23] |
GDC-0199 |
DMH0QKA
|
Major |
Decreased clearance of Ranolazine due to the transporter inhibition by GDC-0199. |
Mature B-cell leukaemia [2A82]
|
[23] |
IPI-145 |
DMWA24P
|
Major |
Decreased metabolism of Ranolazine caused by IPI-145 mediated inhibition of CYP450 enzyme. |
Mature B-cell leukaemia [2A82]
|
[15] |
Arsenic trioxide |
DM61TA4
|
Major |
Increased risk of ventricular arrhythmias by the combination of Ranolazine and Arsenic trioxide. |
Mature B-cell lymphoma [2A85]
|
[68] |
Acalabrutinib |
DM7GCVW
|
Moderate |
Decreased metabolism of Ranolazine caused by Acalabrutinib mediated inhibition of CYP450 enzyme. |
Mature B-cell lymphoma [2A85]
|
[69] |
Ibrutinib |
DMHZCPO
|
Moderate |
Decreased metabolism of Ranolazine caused by Ibrutinib mediated inhibition of CYP450 enzyme. |
Mature B-cell lymphoma [2A85]
|
[70] |
Vincristine |
DMINOX3
|
Moderate |
Decreased metabolism of Ranolazine caused by Vincristine mediated inhibition of CYP450 enzyme. |
Mature B-cell lymphoma [2A85]
|
[71] |
Ponatinib |
DMYGJQO
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Ponatinib. |
Mature B-cell lymphoma [2A85]
|
[15] |
Arry-162 |
DM1P6FR
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Arry-162. |
Melanoma [2C30]
|
[23] |
Vemurafenib |
DM62UG5
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Vemurafenib. |
Melanoma [2C30]
|
[14] |
Selumetinib |
DMC7W6R
|
Moderate |
Decreased metabolism of Ranolazine caused by Selumetinib mediated inhibition of CYP450 enzyme. |
Melanoma [2C30]
|
[72] |
LGX818 |
DMNQXV8
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and LGX818. |
Melanoma [2C30]
|
[73] |
Nitisinone |
DMVS9WQ
|
Moderate |
Decreased metabolism of Ranolazine caused by Nitisinone mediated inhibition of CYP450 enzyme. |
Metabolism inborn error [5C50]
|
[14] |
Methysergide |
DM1EF73
|
Moderate |
Decreased metabolism of Ranolazine caused by Methysergide mediated inhibition of CYP450 enzyme. |
Migraine [8A80]
|
[16] |
Dihydroergotamine |
DM5IKUF
|
Moderate |
Decreased metabolism of Ranolazine caused by Dihydroergotamine mediated inhibition of CYP450 enzyme. |
Migraine [8A80]
|
[53] |
Ubrogepant |
DM749I3
|
Moderate |
Decreased metabolism of Ranolazine caused by Ubrogepant mediated inhibition of CYP450 enzyme. |
Migraine [8A80]
|
[74] |
Propranolol |
DM79NTF
|
Moderate |
Decreased metabolism of Ranolazine caused by Propranolol mediated inhibition of CYP450 enzyme. |
Migraine [8A80]
|
[15] |
Rimegepant |
DMHOAUG
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Rimegepant. |
Migraine [8A80]
|
[75] |
Lasmiditan |
DMXLVDT
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Lasmiditan. |
Migraine [8A80]
|
[76] |
Midazolam |
DMXOELT
|
Moderate |
Decreased metabolism of Ranolazine caused by Midazolam mediated inhibition of CYP450 enzyme. |
Mood/affect symptom [MB24]
|
[71] |
Panobinostat |
DM58WKG
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Panobinostat. |
Multiple myeloma [2A83]
|
[77] |
Thalidomide |
DM70BU5
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Ranolazine and Thalidomide. |
Multiple myeloma [2A83]
|
[23] |
Siponimod |
DM2R86O
|
Major |
Increased risk of ventricular arrhythmias by the combination of Ranolazine and Siponimod. |
Multiple sclerosis [8A40]
|
[23] |
Fingolimod |
DM5JVAN
|
Major |
Increased risk of ventricular arrhythmias by the combination of Ranolazine and Fingolimod. |
Multiple sclerosis [8A40]
|
[14] |
Ozanimod |
DMT6AM2
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Ozanimod. |
Multiple sclerosis [8A40]
|
[18] |
Rifabutin |
DM1YBHK
|
Major |
Increased metabolism of Ranolazine caused by Rifabutin mediated induction of CYP450 enzyme. |
Mycobacterium infection [1B10-1B21]
|
[15] |
Bexarotene |
DMOBIKY
|
Major |
Increased metabolism of Ranolazine caused by Bexarotene mediated induction of CYP450 enzyme. |
Mycosis fungoides [2B01]
|
[15] |
Fedratinib |
DM4ZBK6
|
Major |
Decreased metabolism of Ranolazine caused by Fedratinib mediated inhibition of CYP450 enzyme. |
Myeloproliferative neoplasm [2A20]
|
[15] |
Nilotinib |
DM7HXWT
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Nilotinib. |
Myeloproliferative neoplasm [2A20]
|
[14] |
Ruxolitinib |
DM7Q98D
|
Minor |
Decreased metabolism of Ranolazine caused by Ruxolitinib mediated inhibition of CYP450 enzyme. |
Myeloproliferative neoplasm [2A20]
|
[20] |
Imatinib |
DM7RJXL
|
Major |
Decreased metabolism of Ranolazine caused by Imatinib mediated inhibition of CYP450 enzyme. |
Myeloproliferative neoplasm [2A20]
|
[15] |
Dasatinib |
DMJV2EK
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Dasatinib. |
Myeloproliferative neoplasm [2A20]
|
[18] |
Modafinil |
DMYILBE
|
Major |
Increased metabolism of Ranolazine caused by Modafinil mediated induction of CYP450 enzyme. |
Narcolepsy [7A20]
|
[15] |
Droperidol |
DM0DXA8
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Droperidol. |
Nausea/vomiting [MD90]
|
[14] |
Prochlorperazine |
DM53SRA
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Prochlorperazine. |
Nausea/vomiting [MD90]
|
[18] |
Promethazine |
DM6I5GR
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Promethazine. |
Nausea/vomiting [MD90]
|
[18] |
Rolapitant |
DM8XP26
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Rolapitant. |
Nausea/vomiting [MD90]
|
[78] |
Cyclizine |
DM9G7BS
|
Minor |
Decreased metabolism of Ranolazine caused by Cyclizine mediated inhibition of CYP450 enzyme. |
Nausea/vomiting [MD90]
|
[15] |
Palonosetron |
DMBHMOX
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Palonosetron. |
Nausea/vomiting [MD90]
|
[18] |
Netupitant |
DMEKAYI
|
Major |
Decreased metabolism of Ranolazine caused by Netupitant mediated inhibition of CYP450 enzyme. |
Nausea/vomiting [MD90]
|
[18] |
Granisetron |
DMIUW25
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Granisetron. |
Nausea/vomiting [MD90]
|
[18] |
Dolasetron |
DMMG26Z
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Dolasetron. |
Nausea/vomiting [MD90]
|
[14] |
Ondansetron |
DMOTQ1I
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Ondansetron. |
Nausea/vomiting [MD90]
|
[18] |
Bupropion |
DM5PCS7
|
Minor |
Decreased metabolism of Ranolazine caused by Bupropion mediated inhibition of CYP450 enzyme. |
Nicotine use disorder [6C4A]
|
[15] |
Entrectinib |
DMMPTLH
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Entrectinib. |
Non-small cell lung cancer [2C25]
|
[23] |
Lorcaserin |
DMG6OYJ
|
Minor |
Decreased metabolism of Ranolazine caused by Lorcaserin mediated inhibition of CYP450 enzyme. |
Obesity [5B80-5B81]
|
[15] |
Dexfenfluramine |
DMJ7YDS
|
Moderate |
Decreased metabolism of Ranolazine caused by Dexfenfluramine mediated inhibition of CYP450 enzyme. |
Obesity [5B80-5B81]
|
[15] |
Levomethadyl Acetate |
DM06HG5
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Levomethadyl Acetate. |
Opioid use disorder [6C43]
|
[20] |
Lofexidine |
DM1WXA6
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Lofexidine. |
Opioid use disorder [6C43]
|
[14] |
S-297995 |
DM26IH8
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by S-297995. |
Opioid use disorder [6C43]
|
[20] |
Olaparib |
DM8QB1D
|
Moderate |
Decreased metabolism of Ranolazine caused by Olaparib mediated inhibition of CYP450 enzyme. |
Ovarian cancer [2C73]
|
[79] |
Rucaparib |
DM9PVX8
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Rucaparib. |
Ovarian cancer [2C73]
|
[18] |
Dextropropoxyphene |
DM23HCX
|
Moderate |
Decreased metabolism of Ranolazine caused by Dextropropoxyphene mediated inhibition of CYP450 enzyme. |
Pain [MG30-MG3Z]
|
[15] |
Codeine |
DMJX6ZG
|
Moderate |
Decreased metabolism of Ranolazine caused by Codeine mediated inhibition of CYP450 enzyme. |
Pain [MG30-MG3Z]
|
[80] |
Methamphetamine |
DMPM4SK
|
Moderate |
Decreased metabolism of Ranolazine caused by Methamphetamine mediated inhibition of CYP450 enzyme. |
Pain [MG30-MG3Z]
|
[15] |
Buprenorphine |
DMPRI8G
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Buprenorphine. |
Pain [MG30-MG3Z]
|
[14] |
Oxycodone |
DMXLKHV
|
Major |
Decreased metabolism of Ranolazine caused by Oxycodone mediated inhibition of CYP450 enzyme. |
Pain [MG30-MG3Z]
|
[23] |
Triclabendazole |
DMPWGBR
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Triclabendazole. |
Parasitic worm infestation [1F90]
|
[18] |
Istradefylline |
DM20VSK
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Istradefylline. |
Parkinsonism [8A00]
|
[15] |
Pimavanserin |
DMR7IVC
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Pimavanserin. |
Parkinsonism [8A00]
|
[81] |
Apomorphine |
DMX38HQ
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Apomorphine. |
Parkinsonism [8A00]
|
[18] |
Famotidine |
DMRL3AB
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Famotidine. |
Peptic ulcer [DA61]
|
[23] |
Macimorelin |
DMQYJIR
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Macimorelin. |
Pituitary gland disorder [5A60-5A61]
|
[82] |
Lefamulin |
DME6G97
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Lefamulin. |
Pneumonia [CA40]
|
[83] |
Ergonovine |
DM0VEC1
|
Moderate |
Decreased metabolism of Ranolazine caused by Ergonovine mediated inhibition of CYP450 enzyme. |
Postpartum haemorrhage [JA43]
|
[16] |
Lonafarnib |
DMGM2Z6
|
Major |
Decreased metabolism of Ranolazine caused by Lonafarnib mediated inhibition of CYP450 enzyme. |
Premature ageing appearance [LD2B]
|
[23] |
Ritodrine |
DM4V6RL
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Ritodrine. |
Preterm labour/delivery [JB00]
|
[27] |
Progesterone |
DMUY35B
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Progesterone. |
Preterm labour/delivery [JB00]
|
[15] |
Degarelix |
DM3O8QY
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Degarelix. |
Prostate cancer [2C82]
|
[20] |
ABIRATERONE |
DM8V75C
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and ABIRATERONE. |
Prostate cancer [2C82]
|
[20] |
Nilutamide |
DMFN07X
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Nilutamide. |
Prostate cancer [2C82]
|
[20] |
Enzalutamide |
DMGL19D
|
Major |
Increased metabolism of Ranolazine caused by Enzalutamide mediated induction of CYP450 enzyme. |
Prostate cancer [2C82]
|
[15] |
Flutamide |
DMK0O7U
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Flutamide. |
Prostate cancer [2C82]
|
[20] |
Relugolix |
DMK7IWL
|
Major |
Decreased clearance of Ranolazine due to the transporter inhibition by Relugolix. |
Prostate cancer [2C82]
|
[84] |
Darolutamide |
DMV7YFT
|
Minor |
Decreased metabolism of Ranolazine caused by Darolutamide mediated inhibition of CYP450 enzyme. |
Prostate cancer [2C82]
|
[85] |
Tamsulosin |
DM5QF9V
|
Moderate |
Decreased metabolism of Ranolazine caused by Tamsulosin mediated inhibition of CYP450 enzyme. |
Prostate hyperplasia [GA90]
|
[86] |
Silodosin |
DMJSBT6
|
Moderate |
Decreased metabolism of Ranolazine caused by Silodosin mediated inhibition of CYP450 enzyme. |
Prostate hyperplasia [GA90]
|
[87] |
Alfuzosin |
DMZVMKF
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Alfuzosin. |
Prostate hyperplasia [GA90]
|
[18] |
Levomepromazine |
DMIKFEL
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Levomepromazine. |
Psychotic disorder [6A20-6A25]
|
[18] |
Fluphenazine |
DMIT8LX
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Fluphenazine. |
Psychotic disorder [6A20-6A25]
|
[18] |
Triflupromazine |
DMKFQJP
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Triflupromazine. |
Psychotic disorder [6A20-6A25]
|
[18] |
Bosentan |
DMIOGBU
|
Major |
Increased metabolism of Ranolazine caused by Bosentan mediated induction of CYP450 enzyme. |
Pulmonary hypertension [BB01]
|
[15] |
Riociguat |
DMXBLMP
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Riociguat. |
Pulmonary hypertension [BB01]
|
[23] |
Everolimus |
DM8X2EH
|
Moderate |
Decreased metabolism of Ranolazine caused by Everolimus mediated inhibition of CYP450 enzyme. |
Renal cell carcinoma [2C90]
|
[88] |
Axitinib |
DMGVH6N
|
Moderate |
Decreased metabolism of Ranolazine caused by Axitinib mediated inhibition of CYP450 enzyme. |
Renal cell carcinoma [2C90]
|
[20] |
Sorafenib |
DMS8IFC
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Sorafenib. |
Renal cell carcinoma [2C90]
|
[14] |
Gatifloxacin |
DMSL679
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Gatifloxacin. |
Respiratory infection [CA07-CA4Z]
|
[89] |
Celecoxib |
DM6LOQU
|
Minor |
Decreased metabolism of Ranolazine caused by Celecoxib mediated inhibition of CYP450 enzyme. |
Rheumatoid arthritis [FA20]
|
[15] |
Dexamethasone |
DMMWZET
|
Major |
Increased metabolism of Ranolazine caused by Dexamethasone mediated induction of CYP450 enzyme. |
Rheumatoid arthritis [FA20]
|
[15] |
Nafcillin |
DMN9RPO
|
Major |
Increased metabolism of Ranolazine caused by Nafcillin mediated induction of CYP450 enzyme. |
Rheumatoid arthritis [FA20]
|
[15] |
Oxamniquine |
DM2QDX1
|
Moderate |
Decreased metabolism of Ranolazine caused by Oxamniquine mediated inhibition of CYP450 enzyme. |
Schistosomiasis [1F86]
|
[15] |
Mesoridazine |
DM2ZGAN
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Mesoridazine. |
Schizophrenia [6A20]
|
[14] |
Thioridazine |
DM35M8J
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Thioridazine. |
Schizophrenia [6A20]
|
[14] |
Aripiprazole |
DM3NUMH
|
Moderate |
Decreased metabolism of Ranolazine caused by Aripiprazole mediated inhibition of CYP450 enzyme. |
Schizophrenia [6A20]
|
[90] |
Iloperidone |
DM6AUFY
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Iloperidone. |
Schizophrenia [6A20]
|
[14] |
Paliperidone |
DM7NPJS
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Paliperidone. |
Schizophrenia [6A20]
|
[18] |
Haloperidol |
DM96SE0
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Haloperidol. |
Schizophrenia [6A20]
|
[14] |
Perphenazine |
DMA4MRX
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Perphenazine. |
Schizophrenia [6A20]
|
[18] |
Chlorpromazine |
DMBGZI3
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Chlorpromazine. |
Schizophrenia [6A20]
|
[18] |
Clozapine |
DMFC71L
|
Moderate |
Decreased metabolism of Ranolazine caused by Clozapine mediated inhibition of CYP450 enzyme. |
Schizophrenia [6A20]
|
[15] |
Trifluoperazine |
DMKBYWI
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Trifluoperazine. |
Schizophrenia [6A20]
|
[18] |
Ziprasidone |
DMM58JY
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Ziprasidone. |
Schizophrenia [6A20]
|
[14] |
Risperidone |
DMN6DXL
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Risperidone. |
Schizophrenia [6A20]
|
[18] |
Olanzapine |
DMPFN6Y
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Olanzapine. |
Schizophrenia [6A20]
|
[23] |
Amisulpride |
DMSJVAM
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Amisulpride. |
Schizophrenia [6A20]
|
[91] |
Asenapine |
DMSQZE2
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Asenapine. |
Schizophrenia [6A20]
|
[14] |
Pimozide |
DMW83TP
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Pimozide. |
Schizophrenia [6A20]
|
[20] |
Fentanyl |
DM8WAHT
|
Moderate |
Decreased metabolism of Ranolazine caused by Fentanyl mediated inhibition of CYP450 enzyme. |
Sensation disturbance [MB40]
|
[71] |
Sufentanil |
DMU7YEL
|
Moderate |
Decreased metabolism of Ranolazine caused by Sufentanil mediated inhibition of CYP450 enzyme. |
Sensation disturbance [MB40]
|
[71] |
Vardenafil |
DMTBGW8
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Vardenafil. |
Sexual dysfunction [HA00-HA01]
|
[18] |
Voxelotor |
DMCS6M5
|
Major |
Decreased metabolism of Ranolazine caused by Voxelotor mediated inhibition of CYP450 enzyme. |
Sickle-cell disorder [3A51]
|
[15] |
LDE225 |
DMM9F25
|
Moderate |
Decreased metabolism of Ranolazine caused by LDE225 mediated inhibition of CYP450 enzyme. |
Skin cancer [2C30-2C37]
|
[92] |
Telotristat ethyl |
DMDIYFZ
|
Moderate |
Increased metabolism of Ranolazine caused by Telotristat ethyl mediated induction of CYP450 enzyme. |
Small intestine developmental anomaly [DA90]
|
[20] |
Gefitinib |
DM15F0X
|
Minor |
Decreased metabolism of Ranolazine caused by Gefitinib mediated inhibition of CYP450 enzyme. |
Solid tumour/cancer [2A00-2F9Z]
|
[15] |
Cyclophosphamide |
DM4O2Z7
|
Minor |
Decreased metabolism of Ranolazine caused by Cyclophosphamide mediated inhibition of CYP450 enzyme. |
Solid tumour/cancer [2A00-2F9Z]
|
[20] |
Vinblastine |
DM5TVS3
|
Moderate |
Decreased metabolism of Ranolazine caused by Vinblastine mediated inhibition of CYP450 enzyme. |
Solid tumour/cancer [2A00-2F9Z]
|
[71] |
Docetaxel |
DMDI269
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Docetaxel. |
Solid tumour/cancer [2A00-2F9Z]
|
[93] |
Trabectedin |
DMG3Y89
|
Moderate |
Decreased metabolism of Ranolazine caused by Trabectedin mediated inhibition of CYP450 enzyme. |
Solid tumour/cancer [2A00-2F9Z]
|
[20] |
Armodafinil |
DMGB035
|
Major |
Increased metabolism of Ranolazine caused by Armodafinil mediated induction of CYP450 enzyme. |
Solid tumour/cancer [2A00-2F9Z]
|
[15] |
LEE011 |
DMMX75K
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and LEE011. |
Solid tumour/cancer [2A00-2F9Z]
|
[14] |
Epirubicin |
DMPDW6T
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Epirubicin. |
Solid tumour/cancer [2A00-2F9Z]
|
[18] |
Triptorelin |
DMTK4LS
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Triptorelin. |
Solid tumour/cancer [2A00-2F9Z]
|
[20] |
Doxorubicin |
DMVP5YE
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Doxorubicin. |
Solid tumour/cancer [2A00-2F9Z]
|
[18] |
Vinorelbine |
DMVXFYE
|
Moderate |
Decreased metabolism of Ranolazine caused by Vinorelbine mediated inhibition of CYP450 enzyme. |
Solid tumour/cancer [2A00-2F9Z]
|
[71] |
Pitolisant |
DM8RFNJ
|
Moderate |
Decreased metabolism of Ranolazine caused by Pitolisant mediated inhibition of CYP450 enzyme. |
Somnolence [MG42]
|
[20] |
Telavancin |
DM58VQX
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Telavancin. |
Staphylococcal/streptococcal disease [1B5Y]
|
[18] |
Ibutilide |
DMKXY2R
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Ibutilide. |
Supraventricular tachyarrhythmia [BC81]
|
[14] |
Adenosine |
DMM2NSK
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Ranolazine and Adenosine. |
Supraventricular tachyarrhythmia [BC81]
|
[14] |
Fostamatinib |
DM6AUHV
|
Moderate |
Decreased metabolism of Ranolazine caused by Fostamatinib mediated inhibition of CYP450 enzyme. |
Thrombocytopenia [3B64]
|
[94] |
Lusutrombopag |
DMH6IKO
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Lusutrombopag. |
Thrombocytopenia [3B64]
|
[95] |
Anagrelide |
DMSQ8MD
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Anagrelide. |
Thrombocytosis [3B63]
|
[14] |
Apixaban |
DM89JLN
|
Moderate |
Decreased metabolism of Ranolazine caused by Apixaban mediated inhibition of CYP450 enzyme. |
Thrombosis [DB61-GB90]
|
[20] |
Brilinta |
DMBR01X
|
Moderate |
Decreased clearance of Ranolazine due to the transporter inhibition by Brilinta. |
Thrombosis [DB61-GB90]
|
[15] |
Lenvatinib |
DMB1IU4
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Lenvatinib. |
Thyroid cancer [2D10]
|
[18] |
Papaverine |
DMCA9QP
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Papaverine. |
Tonus and reflex abnormality [MB47]
|
[96] |
Sirolimus |
DMGW1ID
|
Moderate |
Decreased metabolism of Ranolazine caused by Sirolimus mediated inhibition of CYP450 enzyme. |
Transplant rejection [NE84]
|
[71] |
Tacrolimus |
DMZ7XNQ
|
Moderate |
Decreased metabolism of Ranolazine caused by Tacrolimus mediated inhibition of CYP450 enzyme. |
Transplant rejection [NE84]
|
[71] |
Astemizole |
DM2HN6Q
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Astemizole. |
Vasomotor/allergic rhinitis [CA08]
|
[18] |
Chlorpheniramine |
DM5URA2
|
Moderate |
Decreased metabolism of Ranolazine caused by Chlorpheniramine mediated inhibition of CYP450 enzyme. |
Vasomotor/allergic rhinitis [CA08]
|
[15] |
Clemastine |
DMBZWQL
|
Minor |
Decreased metabolism of Ranolazine caused by Clemastine mediated inhibition of CYP450 enzyme. |
Vasomotor/allergic rhinitis [CA08]
|
[15] |
Trimeprazine |
DMEMV9D
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Trimeprazine. |
Vasomotor/allergic rhinitis [CA08]
|
[18] |
Disopyramide |
DM5SYZP
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Disopyramide. |
Ventricular tachyarrhythmia [BC71]
|
[14] |
Mexiletine |
DMCTE9R
|
Moderate |
Decreased metabolism of Ranolazine caused by Mexiletine mediated inhibition of CYP450 enzyme. |
Ventricular tachyarrhythmia [BC71]
|
[15] |
Procainamide |
DMNMXR8
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Procainamide. |
Ventricular tachyarrhythmia [BC71]
|
[14] |
Propafenone |
DMPIBJK
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Propafenone. |
Ventricular tachyarrhythmia [BC71]
|
[18] |
Flecainide |
DMSQDLE
|
Moderate |
Increased risk of prolong QT interval by the combination of Ranolazine and Flecainide. |
Ventricular tachyarrhythmia [BC71]
|
[18] |
Amiodarone |
DMUTEX3
|
Major |
Increased risk of prolong QT interval by the combination of Ranolazine and Amiodarone. |
Ventricular tachyarrhythmia [BC71]
|
[14] |
----------- |
|
|
|
|
|